Janice Knowlton
Medical · Bakersfield, CANPI 1912116096
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 677 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 677 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- GSK$1K
- AstraZeneca$1K
- AbbVie$985
- Novo Nordisk$829
- Otsuka America Pharmaceutical, Inc.$617
- plus $6K from 34 others
What the payments were for
- Food & beverage$12,509100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 157 | $2,182 |
| GSK | 72 | $1,196 |
| AstraZeneca | 47 | $1,191 |
| AbbVie | 47 | $985 |
| Novo Nordisk | 27 | $829 |
| Otsuka America Pharmaceutical, Inc. | 32 | $617 |
| Novartis | 26 | $530 |
| Daiichi Sankyo Inc. | 40 | $502 |
| Pfizer | 27 | $469 |
| Radius Health, Inc. | 19 | $460 |
| Bayer | 17 | $348 |
| Merck | 15 | $328 |
| Lilly USA, LLC | 26 | $297 |
| Boehringer Ingelheim | 11 | $286 |
| Johnson & Johnson | 29 | $272 |
| Corcept Therapeutics | 8 | $236 |
| Heartflow, Inc. | 3 | $191 |
| Phathom Pharmaceuticals, Inc. | 10 | $167 |
| Electromed, Inc. | 6 | $132 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $124 |
| Shield Therapeutics Inc | 5 | $124 |
| Lundbeck LLC | 6 | $119 |
| Baxter Healthcare | 5 | $112 |
| Philips North America LLC | 7 | $110 |
| Verona Pharma, Inc. | 4 | $99 |
| Abbott | 1 | $95 |
| Dexcom, Inc. | 4 | $78 |
| Nevro Corp. | 3 | $73 |
| Esperion Therapeutics, Inc. | 2 | $55 |
| Exact Sciences | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $37 |
| Biosense Webster, Inc. | 1 | $33 |
| Abiomed | 1 | $32 |
| Vertex | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Advanced Respiratory, Inc | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Medtronic | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,509 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 167 | $141,239 |
| OzempicSemaglutide | 85 | $110,779 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $77,467 |
| EliquisApixaban | 80 | $63,416 |
| JanuviaSitagliptin Phosphate | 62 | $55,780 |
| XareltoRivaroxaban | 46 | $52,200 |
| Repatha SureclickEvolocumab | 69 | $43,961 |
| RexultiBrexpiprazole | 18 | $34,007 |
| JardianceEmpagliflozin | 33 | $32,210 |
| ProliaDenosumab | 18 | $30,906 |
| MounjaroTirzepatide | 19 | $25,258 |
| LinzessLinaclotide | 42 | $23,517 |
| MyrbetriqMirabegron | 27 | $16,577 |
| TradjentaLinagliptin | 19 | $12,401 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,191 | $150,065181 claims |
| Novo NordiskOzempic | $829 | $110,77985 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,196 | $85,421104 claims |
| PfizerEliquis, Premarin | $469 | $71,93595 claims |
| MerckJanuvia | $328 | $55,78062 claims |
| Johnson & JohnsonXarelto | $272 | $52,20046 claims |
| Boehringer IngelheimJardiance, Tradjenta | $286 | $44,61052 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $617 | $34,00718 claims |
| AmgenProlia | $2,182 | $30,90618 claims |
| Lilly USA, LLCMounjaro | $297 | $25,25819 claims |
| AbbVieLinzess | $985 | $23,51742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Bakersfield
- Geo MathewBakersfield$20K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- David DoriguzziLancaster$166K
- Deirdre MoxleyFullerton$149K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.